Charts

Xenetic Biosciences ( NASDAQ:XBIO ) Full Year 2023 Results Key Financial Results Revenue: US$2.54m (up 49% from FY...

Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. The post XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the year ended December 31, 2023.

- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform

Gainers PHAXIAM Therapeutics (NASDAQ:PHXM) shares moved upwards by 22.1% to $5.13 during Tuesday's regular session. The market value of ...

Key Insights Xenetic Biosciences will host its Annual General Meeting on 6th of December Total pay for CEO Jeff...

Xenetic Biosciences (NASDAQ:XBIO) reported its Q3 earnings results on Friday, November 10, 2023 at 08:35 AM. Here's what investors need ...

FRAMINGHAM, MA / ACCESSWIRE / November 10, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter ended September 30, 2023.

- Live video webcast interactive Q&A with participating companies -

Live moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ET

FRAMINGHAM, MA / ACCESSWIRE / September 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

- Company continues to execute on plan to advance DNase-based oncology program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

- Event taking place on July 11th, 12th, and 13th -

Live moderated video webcast on Wednesday, July 12th at 10:00 AM ET

Gainers Evelo Biosciences (NASDAQ:EVLO) stock increased by 60.7% to $0.19 during Tuesday's pre-market session. The company's market cap ...

HC Wainwrighthas downgradedXenetic Biosciences Inc(NASDAQ: XBIO)from Buy to Neutral, citing pending clinical ...

Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Gainers ARS Pharmaceuticals (NASDAQ:SPRY) shares increased by 79.4% to $8.11 during Friday's regular session. ARS Pharmaceuticals's ...

FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it will effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on May 15, 2023. Xenetic expects that upon the opening of trading on May 15, 2023, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 602.

- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors

Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise

Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to ...

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used ...

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA ...

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision ...

- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET -

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory ...

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET

Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 34.1% to $0.56 during Thursday's pre-market session. The company's market cap ...

TheFDA issuedan "import alert" about the animal tranquilizer xylazine, also called "tranq," ...

Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 92.8% to $2.28 during Monday's regular session. Cardio Diagnostics Hldgs's ...

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, "Method to Improve Safety and Efficacy of Anti-Cancer Therapy." A patent from the recently allowed application is expected to be issued in the coming months.

- Live video webcast presentations with participating companies -

Live video webcast on Tuesday, January 17th at 10:00 AM ET

Gainers Metacrine (NASDAQ:MTCR) stock increased by 27.0% to $0.45 during Monday's after-market session. Today's trading volume for this ...

During Friday's trading, 293 companies set new 52-week lows. Areas of Significance In Today's 52-Week ...

Gainers Horizon Therapeutics (NASDAQ:HZNP) shares rose 31.8% to $103.8 during Wednesday's pre-market session. The market value of their ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius ...

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platform

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development- Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer.

FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.